RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

Clinical trial NCT06250959 · RECRUITING

Trial details

NCT number: NCT06250959
Sponsor: Chen Suning
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ALL, Adult Philadelphia-Negative ALL

Start date: 2024-02-05
Primary completion: 2025-12-31
Enrollment: 124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.